Bioxytran issues $1.467M in 1-year 6% convertible notes at $0.25; also releases corporate presentation

BIOXYTRAN, INC

Entered 34 Note Purchase Agreements for $1,467,000 principal in convertible notes due Jan 10, 2023; 6% interest, conversion at $0.25/share.
Net cash reduced by $86,040; aggregate discount of $128,290 includes 264,060 five-year warrants at $0.25 issued to placement agent WallachBeth Capital.
Board approved the agreements on Jan 10, 2022; notes issued same day.
Filed corporate presentation (Exhibit 99.1) on Jan 12, 2022 outlining pharmaceutical development status (no specific content provided).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.